Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus Article Swipe
Zhang Yf
,
WI Wei
,
Wang JH
,
Xu Li
,
Jian PE
,
Xiao Cz
,
Zhong XP
,
Minmin Shi
,
Guo RP
·
YOU?
·
· 2016
· Open Access
·
YOU?
·
· 2016
· Open Access
·
Yong-Fa Zhang,1–3,* Wei Wei,1–3,* Jia-Hong Wang,1–3,* Li Xu,1–3 Pei-En Jian,1–3 Cheng-Zuo Xiao,4 Xiao-Ping Zhong,1–3 Ming Shi,1–3 Rong-Ping Guo1–3 1Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, 2State Key Laboratory of Oncology in South China, 3Collaborative Innovation Center for Cancer Medicine, Guangzhou, 4Department of General Surgery, Shenzhen Shajing Affiliated Hospital of Guangzhou Medical University, Shenzhen, People’s Republic of China *These authors contributed equally to this work Objective: To compare the treatment outcomes of sorafenib plus transarterial chemoembolization (TACE) vs TACE alone in patients with hepatocellular carcinoma (HCC) and hepatic vein tumor thrombus (HVTT).Methods: Twenty patients who were initially diagnosed with HCC and HVTT and received TACE combined with sorafenib during February 2009 to October 2013 were included in the study. To minimize selection bias, these patients were compared with 60 case-matched controls selected from a pool of 81 patients (in a 1:3 ratio) who received TACE alone during the same period. The primary end point was overall survival (OS). The secondary end points were time to progression, disease control rate, and adverse events.Results: After a median follow-up period of 12.5 months (range, 1.03–44.23 months), the OS of the combined group was found to be significantly higher compared with the monotherapy group (14.9 vs 6.1 months, P=0.010). The time to progression was found to be significantly longer in the combined group (4.9 vs 2.4 months, P=0.016). Univariate and multivariate analyses revealed that the treatment allocation was an independent predictor of OS.Conclusion: Sorafenib plus TACE was well tolerated and was more effective in treating patients with advanced HCC and HVTT. Future trials with prospective larger samples are required to validate these results. Keywords: hepatocellular carcinoma, hepatic vein tumor thrombus, prognosis, adverse events
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doaj.org/article/017fa27a4b9b452891dcb5c7df1ff052
- OA Status
- green
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4390963538
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4390963538Canonical identifier for this work in OpenAlex
- Title
-
Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombusWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2016Year of publication
- Publication date
-
2016-07-01Full publication date if available
- Authors
-
Zhang Yf, WI Wei, Wang JH, Xu Li, Jian PE, Xiao Cz, Zhong XP, Minmin Shi, Guo RPList of authors in order
- Landing page
-
https://doaj.org/article/017fa27a4b9b452891dcb5c7df1ff052Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://doaj.org/article/017fa27a4b9b452891dcb5c7df1ff052Direct OA link when available
- Concepts
-
Hepatocellular carcinoma, Sorafenib, Medicine, Thrombus, Portal vein, Radiology, Internal medicine, GastroenterologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4390963538 |
|---|---|
| doi | |
| ids.openalex | https://openalex.org/W4390963538 |
| fwci | 0.0 |
| type | article |
| title | Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10073 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9879999756813049 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2721 |
| topics[0].subfield.display_name | Hepatology |
| topics[0].display_name | Hepatocellular Carcinoma Treatment and Prognosis |
| topics[1].id | https://openalex.org/T13779 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9707000255584717 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2734 |
| topics[1].subfield.display_name | Pathology and Forensic Medicine |
| topics[1].display_name | Cancer Mechanisms and Therapy |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2778019345 |
| concepts[0].level | 2 |
| concepts[0].score | 0.9193755388259888 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1148337 |
| concepts[0].display_name | Hepatocellular carcinoma |
| concepts[1].id | https://openalex.org/C2778695046 |
| concepts[1].level | 3 |
| concepts[1].score | 0.8662855625152588 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q421136 |
| concepts[1].display_name | Sorafenib |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.7402873039245605 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2781362458 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6106444001197815 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1588755 |
| concepts[3].display_name | Thrombus |
| concepts[4].id | https://openalex.org/C2779033008 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5698093771934509 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q464543 |
| concepts[4].display_name | Portal vein |
| concepts[5].id | https://openalex.org/C126838900 |
| concepts[5].level | 1 |
| concepts[5].score | 0.5177285075187683 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q77604 |
| concepts[5].display_name | Radiology |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.43242427706718445 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C90924648 |
| concepts[7].level | 1 |
| concepts[7].score | 0.3384968638420105 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[7].display_name | Gastroenterology |
| keywords[0].id | https://openalex.org/keywords/hepatocellular-carcinoma |
| keywords[0].score | 0.9193755388259888 |
| keywords[0].display_name | Hepatocellular carcinoma |
| keywords[1].id | https://openalex.org/keywords/sorafenib |
| keywords[1].score | 0.8662855625152588 |
| keywords[1].display_name | Sorafenib |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.7402873039245605 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/thrombus |
| keywords[3].score | 0.6106444001197815 |
| keywords[3].display_name | Thrombus |
| keywords[4].id | https://openalex.org/keywords/portal-vein |
| keywords[4].score | 0.5698093771934509 |
| keywords[4].display_name | Portal vein |
| keywords[5].id | https://openalex.org/keywords/radiology |
| keywords[5].score | 0.5177285075187683 |
| keywords[5].display_name | Radiology |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.43242427706718445 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/gastroenterology |
| keywords[7].score | 0.3384968638420105 |
| keywords[7].display_name | Gastroenterology |
| language | en |
| locations[0].id | pmh:oai:doaj.org/article:017fa27a4b9b452891dcb5c7df1ff052 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4306401280 |
| locations[0].source.issn | |
| locations[0].source.type | repository |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[0].source.host_organization | |
| locations[0].source.host_organization_name | |
| locations[0].license | cc-by-sa |
| locations[0].pdf_url | |
| locations[0].version | submittedVersion |
| locations[0].raw_type | article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[0].is_accepted | False |
| locations[0].is_published | False |
| locations[0].raw_source_name | OncoTargets and Therapy, Vol 2016, Iss Issue 1, Pp 4239-4246 (2016) |
| locations[0].landing_page_url | https://doaj.org/article/017fa27a4b9b452891dcb5c7df1ff052 |
| indexed_in | doaj |
| authorships[0].author.id | https://openalex.org/A5110154339 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Zhang Yf |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Zhang YF |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5100323733 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-6281-7126 |
| authorships[1].author.display_name | WI Wei |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Wei W |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5086727437 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Wang JH |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Wang JH |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5100327132 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-7887-4694 |
| authorships[3].author.display_name | Xu Li |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Xu L |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5113098428 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Jian PE |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Jian PE |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5029783198 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Xiao Cz |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Xiao CZ |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5021975423 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Zhong XP |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Zhong XP |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5102956503 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-1935-5090 |
| authorships[7].author.display_name | Minmin Shi |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Shi M |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5093734386 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Guo RP |
| authorships[8].author_position | last |
| authorships[8].raw_author_name | Guo RP |
| authorships[8].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doaj.org/article/017fa27a4b9b452891dcb5c7df1ff052 |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T04:12:42.849631 |
| primary_topic.id | https://openalex.org/T10073 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9879999756813049 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2721 |
| primary_topic.subfield.display_name | Hepatology |
| primary_topic.display_name | Hepatocellular Carcinoma Treatment and Prognosis |
| related_works | https://openalex.org/W2415536161, https://openalex.org/W2087356637, https://openalex.org/W2034139851, https://openalex.org/W3018861914, https://openalex.org/W4285206599, https://openalex.org/W2769323635, https://openalex.org/W1970460092, https://openalex.org/W4361816912, https://openalex.org/W4362622788, https://openalex.org/W2280419820 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | pmh:oai:doaj.org/article:017fa27a4b9b452891dcb5c7df1ff052 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306401280 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| best_oa_location.source.host_organization | |
| best_oa_location.source.host_organization_name | |
| best_oa_location.license | cc-by-sa |
| best_oa_location.pdf_url | |
| best_oa_location.version | submittedVersion |
| best_oa_location.raw_type | article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-sa |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | OncoTargets and Therapy, Vol 2016, Iss Issue 1, Pp 4239-4246 (2016) |
| best_oa_location.landing_page_url | https://doaj.org/article/017fa27a4b9b452891dcb5c7df1ff052 |
| primary_location.id | pmh:oai:doaj.org/article:017fa27a4b9b452891dcb5c7df1ff052 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4306401280 |
| primary_location.source.issn | |
| primary_location.source.type | repository |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| primary_location.source.host_organization | |
| primary_location.source.host_organization_name | |
| primary_location.license | cc-by-sa |
| primary_location.pdf_url | |
| primary_location.version | submittedVersion |
| primary_location.raw_type | article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-sa |
| primary_location.is_accepted | False |
| primary_location.is_published | False |
| primary_location.raw_source_name | OncoTargets and Therapy, Vol 2016, Iss Issue 1, Pp 4239-4246 (2016) |
| primary_location.landing_page_url | https://doaj.org/article/017fa27a4b9b452891dcb5c7df1ff052 |
| publication_date | 2016-07-01 |
| publication_year | 2016 |
| referenced_works_count | 0 |
| abstract_inverted_index.a | 133, 139, 173 |
| abstract_inverted_index.60 | 128 |
| abstract_inverted_index.81 | 136 |
| abstract_inverted_index.Li | 6 |
| abstract_inverted_index.OS | 182 |
| abstract_inverted_index.To | 66, 119 |
| abstract_inverted_index.an | 230 |
| abstract_inverted_index.be | 190, 209 |
| abstract_inverted_index.in | 32, 80, 116, 212, 245 |
| abstract_inverted_index.of | 19, 30, 43, 50, 57, 71, 135, 177, 183, 233 |
| abstract_inverted_index.to | 111, 164, 189, 204, 208, 261 |
| abstract_inverted_index.vs | 77, 199, 217 |
| abstract_inverted_index.(in | 138 |
| abstract_inverted_index.1:3 | 140 |
| abstract_inverted_index.HCC | 99, 250 |
| abstract_inverted_index.Key | 28 |
| abstract_inverted_index.Sun | 22 |
| abstract_inverted_index.The | 150, 158, 202 |
| abstract_inverted_index.Wei | 2 |
| abstract_inverted_index.and | 86, 100, 102, 169, 221, 241, 251 |
| abstract_inverted_index.are | 259 |
| abstract_inverted_index.end | 152, 160 |
| abstract_inverted_index.for | 38 |
| abstract_inverted_index.the | 68, 117, 147, 181, 184, 195, 213, 226 |
| abstract_inverted_index.was | 154, 187, 206, 229, 238, 242 |
| abstract_inverted_index.who | 94, 142 |
| abstract_inverted_index.(4.9 | 216 |
| abstract_inverted_index.2009 | 110 |
| abstract_inverted_index.2013 | 113 |
| abstract_inverted_index.HVTT | 101 |
| abstract_inverted_index.Ming | 14 |
| abstract_inverted_index.TACE | 78, 104, 144, 237 |
| abstract_inverted_index.from | 132 |
| abstract_inverted_index.more | 243 |
| abstract_inverted_index.plus | 73, 236 |
| abstract_inverted_index.pool | 134 |
| abstract_inverted_index.same | 148 |
| abstract_inverted_index.that | 225 |
| abstract_inverted_index.time | 163, 203 |
| abstract_inverted_index.vein | 88, 269 |
| abstract_inverted_index.well | 239 |
| abstract_inverted_index.were | 95, 114, 125, 162 |
| abstract_inverted_index.with | 82, 98, 106, 127, 194, 248, 255 |
| abstract_inverted_index.work | 64 |
| abstract_inverted_index.(14.9 | 198 |
| abstract_inverted_index.(HCC) | 85 |
| abstract_inverted_index.(OS). | 157 |
| abstract_inverted_index.After | 172 |
| abstract_inverted_index.China | 58 |
| abstract_inverted_index.HVTT. | 252 |
| abstract_inverted_index.South | 33 |
| abstract_inverted_index.alone | 79, 145 |
| abstract_inverted_index.bias, | 122 |
| abstract_inverted_index.found | 188, 207 |
| abstract_inverted_index.group | 186, 197, 215 |
| abstract_inverted_index.point | 153 |
| abstract_inverted_index.rate, | 168 |
| abstract_inverted_index.these | 123, 263 |
| abstract_inverted_index.tumor | 89, 270 |
| abstract_inverted_index.(TACE) | 76 |
| abstract_inverted_index.*These | 59 |
| abstract_inverted_index.2State | 27 |
| abstract_inverted_index.Cancer | 25, 39 |
| abstract_inverted_index.Center | 37 |
| abstract_inverted_index.China, | 34 |
| abstract_inverted_index.Future | 253 |
| abstract_inverted_index.Pei-En | 8 |
| abstract_inverted_index.Twenty | 92 |
| abstract_inverted_index.Xiao,4 | 11 |
| abstract_inverted_index.during | 108, 146 |
| abstract_inverted_index.events | 274 |
| abstract_inverted_index.higher | 192 |
| abstract_inverted_index.larger | 257 |
| abstract_inverted_index.longer | 211 |
| abstract_inverted_index.median | 174 |
| abstract_inverted_index.period | 176 |
| abstract_inverted_index.points | 161 |
| abstract_inverted_index.ratio) | 141 |
| abstract_inverted_index.study. | 118 |
| abstract_inverted_index.trials | 254 |
| abstract_inverted_index.(range, | 179 |
| abstract_inverted_index.Center, | 26 |
| abstract_inverted_index.General | 44 |
| abstract_inverted_index.Medical | 52 |
| abstract_inverted_index.October | 112 |
| abstract_inverted_index.Shajing | 47 |
| abstract_inverted_index.Yat-sen | 23 |
| abstract_inverted_index.Yong-Fa | 0 |
| abstract_inverted_index.adverse | 170, 273 |
| abstract_inverted_index.authors | 60 |
| abstract_inverted_index.compare | 67 |
| abstract_inverted_index.control | 167 |
| abstract_inverted_index.disease | 166 |
| abstract_inverted_index.equally | 62 |
| abstract_inverted_index.hepatic | 87, 268 |
| abstract_inverted_index.overall | 155 |
| abstract_inverted_index.period. | 149 |
| abstract_inverted_index.primary | 151 |
| abstract_inverted_index.samples | 258 |
| abstract_inverted_index.February | 109 |
| abstract_inverted_index.Hospital | 49 |
| abstract_inverted_index.Jia-Hong | 4 |
| abstract_inverted_index.Oncology | 31 |
| abstract_inverted_index.Republic | 56 |
| abstract_inverted_index.Shenzhen | 46 |
| abstract_inverted_index.Surgery, | 45 |
| abstract_inverted_index.advanced | 249 |
| abstract_inverted_index.analyses | 223 |
| abstract_inverted_index.combined | 105, 185, 214 |
| abstract_inverted_index.compared | 126, 193 |
| abstract_inverted_index.controls | 130 |
| abstract_inverted_index.included | 115 |
| abstract_inverted_index.minimize | 120 |
| abstract_inverted_index.outcomes | 70 |
| abstract_inverted_index.patients | 81, 93, 124, 137, 247 |
| abstract_inverted_index.received | 103, 143 |
| abstract_inverted_index.required | 260 |
| abstract_inverted_index.results. | 264 |
| abstract_inverted_index.revealed | 224 |
| abstract_inverted_index.selected | 131 |
| abstract_inverted_index.survival | 156 |
| abstract_inverted_index.thrombus | 90 |
| abstract_inverted_index.treating | 246 |
| abstract_inverted_index.validate | 262 |
| abstract_inverted_index.Cheng-Zuo | 10 |
| abstract_inverted_index.Guangzhou | 51 |
| abstract_inverted_index.Keywords: | 265 |
| abstract_inverted_index.Medicine, | 40 |
| abstract_inverted_index.Oncology, | 21 |
| abstract_inverted_index.P=0.010). | 201 |
| abstract_inverted_index.P=0.016). | 219 |
| abstract_inverted_index.Rong-Ping | 16 |
| abstract_inverted_index.Shenzhen, | 54 |
| abstract_inverted_index.Sorafenib | 235 |
| abstract_inverted_index.Xiao-Ping | 12 |
| abstract_inverted_index.carcinoma | 84 |
| abstract_inverted_index.diagnosed | 97 |
| abstract_inverted_index.effective | 244 |
| abstract_inverted_index.follow-up | 175 |
| abstract_inverted_index.initially | 96 |
| abstract_inverted_index.predictor | 232 |
| abstract_inverted_index.secondary | 159 |
| abstract_inverted_index.selection | 121 |
| abstract_inverted_index.sorafenib | 72, 107 |
| abstract_inverted_index.thrombus, | 271 |
| abstract_inverted_index.tolerated | 240 |
| abstract_inverted_index.treatment | 69, 227 |
| abstract_inverted_index.Affiliated | 48 |
| abstract_inverted_index.Guangzhou, | 41 |
| abstract_inverted_index.Innovation | 36 |
| abstract_inverted_index.Laboratory | 29 |
| abstract_inverted_index.Objective: | 65 |
| abstract_inverted_index.Univariate | 220 |
| abstract_inverted_index.University | 24 |
| abstract_inverted_index.allocation | 228 |
| abstract_inverted_index.carcinoma, | 267 |
| abstract_inverted_index.prognosis, | 272 |
| abstract_inverted_index.1Department | 18 |
| abstract_inverted_index.4Department | 42 |
| abstract_inverted_index.University, | 53 |
| abstract_inverted_index.contributed | 61 |
| abstract_inverted_index.independent | 231 |
| abstract_inverted_index.monotherapy | 196 |
| abstract_inverted_index.progression | 205 |
| abstract_inverted_index.prospective | 256 |
| abstract_inverted_index.case-matched | 129 |
| abstract_inverted_index.multivariate | 222 |
| abstract_inverted_index.progression, | 165 |
| abstract_inverted_index.Hepatobiliary | 20 |
| abstract_inverted_index.significantly | 191, 210 |
| abstract_inverted_index.transarterial | 74 |
| abstract_inverted_index.3Collaborative | 35 |
| abstract_inverted_index.OS.Conclusion: | 234 |
| abstract_inverted_index.hepatocellular | 83, 266 |
| abstract_inverted_index.(HVTT).Methods: | 91 |
| abstract_inverted_index.events.Results: | 171 |
| abstract_inverted_index.Guo1–3 | 17 |
| abstract_inverted_index.Xu,1–3 | 7 |
| abstract_inverted_index.to this | 63 |
| abstract_inverted_index.Shi,1–3 | 15 |
| abstract_inverted_index.chemoembolization | 75 |
| abstract_inverted_index.Jian,1–3 | 9 |
| abstract_inverted_index.People’s | 55 |
| abstract_inverted_index.Wei,1–3,* | 3 |
| abstract_inverted_index.Zhong,1–3 | 13 |
| abstract_inverted_index.12.5 months | 178 |
| abstract_inverted_index.2.4 months, | 218 |
| abstract_inverted_index.6.1 months, | 200 |
| abstract_inverted_index.Wang,1–3,* | 5 |
| abstract_inverted_index.Zhang,1–3,* | 1 |
| abstract_inverted_index.1.03–44.23 months), | 180 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 9 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7599999904632568 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.34678409 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |